Pancreatic cancer most commonly spreads to the liver, followed by the peritoneum (the lining of the abdominal cavity) and the lungs. Among patients diagnosed with stage IV pancreatic cancer, about 74% have liver metastases, 19% have lung involvement, and roughly 6% have bone spread. Less common sites include the brain, skin, kidneys, and other organs.
About half of all pancreatic cancer patients already have metastatic disease at the time of diagnosis, and the five-year survival rate for distant-stage disease is 3.2%. Understanding where the cancer travels helps explain the symptoms patients experience and the monitoring strategies doctors use.
Liver: The Most Common Destination
The liver receives the vast majority of pancreatic cancer metastases. This isn’t a coincidence. Blood draining from the pancreas flows directly into the portal vein, which feeds the liver, giving cancer cells a direct route. In a large population study using the SEER cancer database, liver metastases accounted for over 74% of all recorded distant spread sites among patients with metastatic pancreatic cancer.
When pancreatic cancer reaches the liver, it can cause jaundice (yellowing of the skin and eyes), abdominal swelling, nausea, and loss of appetite. Some patients develop fluid buildup in the abdomen. Liver metastases also tend to carry a worse prognosis than spread to other sites. Patients with isolated liver metastases have shorter survival compared to those whose cancer spreads only to the lungs or distant lymph nodes.
Peritoneum: Often Hidden on Imaging
The peritoneum, the thin membrane lining the abdominal cavity and covering the organs inside it, is the second most common site of metastasis. Only about 10% of patients show visible peritoneal spread at the time of their initial diagnosis, but that number is misleadingly low. Up to 50% of patients who undergo surgery with the intent to cure their cancer eventually develop peritoneal metastases. Autopsy studies find peritoneal involvement in half of all patients at the time of death.
One reason peritoneal spread is underreported is that standard CT imaging can underestimate its extent by 20 to 30% compared to what surgeons see directly during an operation. Another 20 to 30% of patients have cancer cells detectable in abdominal fluid even without any visible tumors on the peritoneal surface, a sign of disease that hasn’t yet formed identifiable masses.
Peritoneal metastases cause some of the most quality-of-life-altering symptoms of advanced pancreatic cancer. These include painful fluid buildup in the abdomen (ascites), bowel obstruction (which occurs in up to 28% of cases), urinary obstruction, and accelerated weight loss. The combination of these problems frequently drives both suffering and mortality in late-stage disease.
Lungs: A Better Prognosis Than Other Sites
Lung metastases from pancreatic cancer occur in roughly 19% of patients with distant spread. In autopsy studies, the lungs consistently rank as the third most common site after the liver and peritoneum. In some cases, cancer cells bypass the liver entirely and reach the lungs through the bloodstream.
There is a notable finding about lung-only metastases: patients whose pancreatic cancer spreads exclusively to the lungs tend to survive longer than those with isolated liver or peritoneal disease. The reasons aren’t entirely clear, but it may reflect a biologically less aggressive tumor subtype or a pattern of spread that takes longer to develop.
Bones: Spine, Hips, and Ribs
Bone metastases are less common, estimated at 5 to 20% of patients over the course of their disease, though one retrospective review found a rate as low as 2.2% in a single institution’s records. When pancreatic cancer does reach the skeleton, it has a strong preference for certain locations. The spine is affected in virtually every case of bone spread. The hips and ribs are the next most frequent sites, each involved in over half of patients with skeletal metastases. Spread to the arms, legs, skull, or face is much rarer.
Bone metastases cause deep, persistent pain that often worsens at night or with movement. They can also weaken bone to the point of fracture, sometimes before anyone realizes the cancer has spread there.
Brain and Other Rare Sites
Brain metastases from pancreatic cancer are genuinely rare. Only about 0.25% of metastatic patients in the SEER database had brain involvement, and as of the most recent published review, only around 12 cases had been documented in the medical literature. In a few of those cases, a brain metastasis was actually the first sign of the underlying pancreatic cancer.
Other unusual destinations include the skin, kidneys, thyroid gland, intestine, heart, and testes. These are reported as individual case studies rather than common patterns, but they illustrate that pancreatic cancer cells can, in principle, travel almost anywhere through the bloodstream.
How the Cancer Spreads
Pancreatic cancer uses several routes to leave the pancreas. The most straightforward is hematogenous spread, where cancer cells enter the bloodstream and travel to distant organs, particularly the liver and lungs. Lymphatic spread carries cells into nearby and eventually distant lymph nodes. Chemical signals produced by lymphatic tissue actually attract pancreatic cancer cells, guiding them along these pathways like a trail.
A third route, perineural invasion, is especially characteristic of pancreatic cancer. Cancer cells grow along and around nerves, using the nerve sheath as a highway. This is one reason pancreatic cancer causes such severe pain even in its earlier stages, and it contributes to local spread and recurrence after surgery. This nerve-seeking behavior is driven by specific chemical interactions between the tumor and surrounding nerve tissue.
How Metastases Are Detected
CT scans are the primary tool for identifying pancreatic cancer spread, particularly to the liver and lymph nodes. They’re used both at initial diagnosis and for ongoing monitoring after treatment. PET scans, often combined with CT, help detect metabolically active cancer deposits that might not show clearly on CT alone. MRI provides detailed images and is especially useful for evaluating specific organs when CT findings are uncertain.
Despite these tools, peritoneal spread remains notoriously difficult to detect on imaging. Small tumor deposits scattered across the abdominal lining simply don’t show up reliably on standard scans, which is why surgical exploration sometimes reveals disease that imaging missed entirely.